Clinical assessment of saxagliptin therapy in diabetic patients with corpulence
Department of Pharmaceutics, College of Pharmacy, Al-Nahrain University, Iraq.
Research Article
GSC Biological and Pharmaceutical Sciences, 2022, 21(01), 109–115.
Article DOI: 10.30574/gscbps.2022.21.1.0389
Publication history:
Received on 07 September 2022; revised on 10 October 2022; accepted on 13 October 2022
Abstract:
Saxagliptin is an oral hypoglycemic agent act by inhibiting dipeptidyl peptidase 4 and prescribed for the management of diabetes alone or with other anti-diabetic drug. The idea of the research is to clarify the impact of saxagliptin treatment on adipokines of corpulence in diabetic patients. Of seventy-three diabetic patients with corpulence (43 males and 30 females), aging (45± 7) years of either sex were appointed to take Saxagliptin (5 mg/day) for 5 months periods. Data were pooled on fasting state prior treatment and after five months treatment. The variables involved body mass index, HOMA -IR, blood levels of lipid profile, glucose, insulin, visfatin, adiponectin, and leptin. The results of this treatment approach yielded high significant reduction in the sign of body mass (P<0.0002), and in the blood levels of hemoglobin A1c percentage (P<0.0002), lipid profiles (P<0.005), fasting glucose (P<0.0002), leptin (P<0.01), and visfatin (P<0.005). Contrarily, a high significant elevation (P<0.005) in adiponectin levels was reported. Eventually, Saxagliptin treatment modulate glycemic index and lessen patient’s weight. As well, attenuation in insulin resistance index and in blood levels of leptin and visfatin were achieved. Likewise, the blood level of adiponectin was ameliorated.
Keywords:
Adiponectin; Glycemic index; Leptin; Visfatin
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
